Solide Tumoren - Atemwege und Lunge - Mesotheliome -

Weiterführende Informationen

Studien

www.studien.de; Kontaktadressen: Arbeitsgruppe „Lungenkarzinome der AIO“: Dr. Wilfried Eberhardt, Innere Klinik-Tumorforschung, Westdeutsches Tumorzentrum, Essen, E-Mail: wilfried.eberhardt@uni-essen.de

Pneumologisch-Onkologische Arbeitsgemeinschaft (POA) der DKG, Prof. Dr. D. Ukena, Klinikum Bremen-Ost, E-Mail: dieter.ukena@klinikum-bremen-ost.de

Literatur

Übersicht im Internet: http://www.malignesmesotheliom.de/index.htm

1. De Perrot M et al: Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Clin Oncol 2009; 27: 1413–8
2. Sugarbaker DJ et al: Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma. J Thorac Cardiovasc Surg 1999; 117: 54–65
3. Ceresoli GL et al: Phase II study of pemetrexed plus carboplatin in malignant mesothelioma. J Clin Oncol 2006; 24: 1443–8
4. Santoro A et al: Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program. J Thorac Oncol. 2008; 3: 756–63
5. Krug LM et al: A multicenter U.S. trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation malignant pleural mesothelioma. J Clin Oncol. 2009; 27: 3007–13